СORONAVIRUS INFECTION WITH AN OBESITY
| Autor: | S. N. Ionov, S. S. Saidov, O. V. Abanina, M. Yu. Petrov, E. S. Klimova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье, Vol 0, Iss 3, Pp 13-19 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2226-762X 2782-1579 |
| DOI: | 10.20340/vmi-rvz.2021.3.COVID.2 |
| Popis: | Summary. Relevance of the topic: most of the world is obese and there are enough cases of the impact of this pathology on the development of a complicated and severe course of novel coronavirus (COVID-19)infection. Purpose of the study: to study literature data on the effect of obesity on the course of novel coronavirus infection. Objectives: 1. To consider obesity as a factor contributing to the intensification of inflammatory reactions. 2. To study the etiology and pathogenesis of COVID-19 infection. 3. To establish the relationship between obesity and complications arising from coronavirus infection. Results. The most common feature of COVID-19 is severe acute respiratory syndrome caused by progressive lung consolidation. There is a positive correlation between the duration of COVID-19 infection and the degree of interstitial fibrosis. Extensive pulmonary fibrosis is one of the main causes of pulmonary consolidation due to the excessive extracellular matrix component produced by activated myofibroblasts [7]. Pulmonary lipofibroblasts are a special type of adipocytes that contain typical lipid droplets and are close to the second type of alveolar epithelial cells of the pulmonary interstitium. Lipofibroblasts may result from ectopic fat deposition, which plays a vital role in the progression of COVID-19 in these patients. When exposed to various stimulants, such as hyperoxia and infection of lung lipofibroblasts, a transdifferentiated myogenic phenotype called myofibroblasts occurs, which causes pulmonary fibrosis [10]. A significant number of obese patients have impaired glucose metabolism, which is considered a risk factor and leads to death. SARS infection has been found to cause hyperglycemia in some patients due to dysfunction of the islets of the pancreas as a result of a viral attack. A similar effect occurs after infection with SARS-COV-2. This explains why 52% of those infected with SARS-COV-2 had hyperglycemia. The level of glucose increase in metabolic disorders in obese patients can be much higher. Hyperglycemia leads to a number of complications, including osmotic imbalance of fluid and electrolytes, hyperosmolar non-ketonemic coma, worsening skeletal muscle catabolism, impaired wound healing, altered coagulation, and increased susceptibility to infections [4]. In addition, hyperglycemia impairs the body's immune function. All of this worsens the clinical outcome of COVID-19. Notably, proper blood glucose control reduces mortality in critically ill patients, highlighting the importance of blood glucose control. Conclusion. The relationship between obesity as a factor complicating the course of SARS-COV-2 infection has been shown. This mainly concerns the development of a cytokine storm due to the release of IL-1, IL-6, IL-10 by adipose tissue, as well as TNF-α. It should be noted that obesity affects the occurrence of concomitant metabolic diseases in patients, such as type 2 diabetes mellitus, coronary heart disease, atherosclerosis, etc., leading to acute myocardial infarction, increased thrombus formation and many other serious conditions. In addition, it is difficult for obese patients to provide specialized medical care when connecting to a ventilator, preventing pressure ulcers and attaching a secondary infection. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|